MelnickA, LichtID. Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood1999;93:3167–215.
5.
HeLZ, GuidezF, TribioliC, PeruzziD, RuthardtM, ZelentA, PandolfiPP. Distinct interactions of PML-RAR and PLZF-RARa with co-repressors determine differential responses to RA in APL. Nat Genet1998;18:126–35.
6.
GrignaniF, DeMatteisS, NerviC, TomassoniL, GelmettiV, CioceM, FanelliM, RuthardtM, FerraraFF, ZamirI.Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukemia. Nature1998;391:815–8.
7.
LinRJ, NagyL, InoueS, ShaoW, MillerWHJr, EvansRM. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature1998;391:811–4.
8.
HongSH, DavidG, WongCW, DejeanA, PrivalskyML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor a and PLZF-RARa oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA1997;94:9028–33.
9.
WangJ, HoshinoT, RednerRL, KajigayaS, LiuJM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA1998;95:10860–5.
10.
LutterbachB, WestendorfJJ, LinggiB, PattenA, MoniwaM, DavieJR, HuynhKD, BardwellVJ, LavinskyRM, RosenfeldMG, . ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol1998;18:7176–84.
11.
GelmettiV, ZhangJ, FanelliM, MinucciS, PelicciPG, LazarMA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol1998;18:7185–91.
12.
HenryRR. Thiazolidinediones. Endocrinol Metab Clin North Am1997;26:553–73.
13.
KletzienRF, ClarkeSD, UlrichRG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol1992;41:393–8.
14.
ChawlaA, LazarMA. Peroxisome proliferator and retinoid signaling pathways coregulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA1994;91:1786–90.
15.
ChawlaA, SchwarzEJ, DimaculanganDD, LazarMA. Peroxisome proliferator-activated receptor y (PPARY): adipose predominant expression and induction early in adipocyte differentiation. Endocrinology1994;135:798–800.
16.
TontonozP, HuE, GravesRA, BudavariAl, SpiegelmanBM. mPPARY2: tissue-specific regulator of an adipocyte enhancer. Genes Dev1994;8:1224–34.
17.
TontonozP, HuE, DevineJ, BealeKG, SpiegelmanBM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol1995;15:351–7.
18.
LehmannJM, MooreLB, Smith-OliverTA, WilkisonWO, WillsonTM, KliewerSA. An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor y (PPARY). J Biol Chem1995;270:12953–6.
ShibataH, SpencerTE, OnateSA, JensterG, TsaiSY, TsaiMJ, O'MalleyBW. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res1997;52:141–64.
21.
CasiniT, GrignaniF, PelicciPG. Genetics of APL and the molecular basis of retinoic acid treatment. Int J Cancer1997;70:473–4.
